Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DA-001 · 1 trial · 6 indications
Number of hairs shedding during brushing at target area
| Arm | Type | Description |
|---|---|---|
| DA-001 Topical | EXPERIMENTAL | Phenylephrine 2.5% Topical + TAAR agonist |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Phenylephrine Topical | EXPERIMENTAL | Phenylephrine 2.5% Topical (per application volume - males 5mL and females 20mL) |
| DA-001 Topical + DA-005 Oral (HIF-1α supplement) | EXPERIMENTAL | DA-001 Topical (Phenylephrine 2.5% Topical + TAAR agonist tyramine) + DA-005 Oral (HIF-1α supplement) |
| DA-010 - Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement) | EXPERIMENTAL | Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement) |
| Phenylephrine Topical 0.25% + Intact Pro Topical | EXPERIMENTAL | Phenylephrine Topical 0.25% + Intact Pro Topical |
| Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement) | EXPERIMENTAL | Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement) |
| Name | Type | Description |
|---|---|---|
| DA-001 | DRUG | Phenylephrine 2.5% Topical + TAAR Agonist (GRAS) Topical Solution |
| Placebo | OTHER | Placebo Topical Solution |
| Phenylephrine | DRUG | Phenylephrine 2.5% Topical |
| DA-001 Topical + DA-005 Oral (HIF-1α supplement) | OTHER | DA-001 Topical (Phenylephrine 2.5% Topical + TAAR agonist tyramine) + DA-005 Oral (HIF-1α supplement) |
| DA-010 - Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement) | OTHER | Oral Phenylephrine 20 mg + DA-005 Oral (HIF-1α supplement) |
| Phenylephrine Topical 0.25% + Intact Pro Topical | DRUG | Phenylephrine 0.25% + Intact Pro (50% stronger) |
| Phenylephrine + Intact Pro + DA-005 Oral (HIF-1α supplement) | OTHER | Phenylephrine 0.25% + Intact Pro (50% stronger) + DA-005 Oral (HIF-1α supplement) |
Inclusion Criteria: * Age 18 or older * Diagnosed with telogen effluvium * Willing and able to apply the treatment as directed, comply with study * Otherwise healthy * Able to give informed consent Exclusion Criteria: * A medical history that may interfere with study objectives * Women who are pr...
DA-001 is an investigational small molecule being developed for the treatment of Telogen Effluvium, a form of temporary hair shedding. It is also being studied for related hair loss conditions including Female Pattern Hair Loss, Androgenic Alopecia, Male Pattern Baldness, and Androgenetic Alopecia (AGA).
DA-001 is being developed by Applied Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol APLT. The company is conducting clinical research to evaluate the safety and efficacy of DA-001 for hair loss conditions.
DA-001 is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 2 clinical trial is planned to evaluate its effects on hair shedding reduction and hair regrowth.
DA-001 is being studied in a Phase 2 clinical trial registered as NCT06648850, titled "Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth." The trial is not yet recruiting and aims to enroll approximately 1,120 participants.
Yes, the Phase 2 clinical trial of DA-001 is randomized, double-blind, and placebo-controlled. This design helps ensure that the results are reliable by comparing the effects of DA-001 against a placebo in a blinded manner.